CD8A and neoplasm: Following a 22 days ex vivo expansion, the tumor-specific memory reactivity of PLO CD8+ T cells of mice treated IT with mPH-762 was compared to treatment with IT NTC or IT PBS, by challenge with intact matched (Hepa1-6) or mismatched (CT26) tumor cells.